cartitude-2: efficacy and safety of ciltacabtagene autoleucel in patients with progressive mm
Published 3 years ago • 385 plays • Length 7:23Download video MP4
Download video MP3
Similar videos
-
4:25
updated results from cartitude-1: phase 1b/2study of cilta-cel in pts with rr multiple myeloma
-
8:45
updates on clinical data of cilta-cel in cartitude-2 cohort a among progressive mm patients
-
6:54
ash23: cartitude-2 trial on ciltacabtagene autoleucel in multiple myeloma | jens hillengass, md, phd
-
9:34
neurologic adverse effects in pts with mm treated with cilta-cel in cartitude-2
-
5:42
ciltacabtagene autoleucel in cartitude-1 vs standard of care in triple-class exposed mm pts
-
5:03
cartitude-2: evaluating car t therapy cilta-cel in multiple myeloma patients who had early relapse
-
1:21
an update on cartitude-2: cilta-cel in patients with multiple myeloma in second line
-
5:42
comparison of outcomes with cilta-cel in cartitude-1 vs rw soc for pts w/ triple-class exposed rrmm
-
4:23
ciltacabtagene autoleucel vs belantamab mafodotin in rrmm pts with ≥3 lines of prior therapy
-
9:03
cartitude-1: final results of ciltacabtagene autoleucel in heavily pretreated relapsed refractory mm
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
2:23
ciltacabtagene autoleucel in rrmm: updated results from cartitude-1
-
4:28
comparison of cartitude-1 outcomes vs real world clinical practice observed in german registry
-
3:37
updated data from cartitude-1 and cartitude-2 studies testing cilta-cel in r/r multiple myeloma
-
5:46
outcomes from the cartitude-1 study assessing car t-cell therapy in rr multiple myeloma
-
4:10
cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma
-
6:43
cartitude-4 cilta-cel efficacy in myeloma | binod dhakal, md | asco 2023
-
3:54
update of cartitude-1: a phase ib/ii study of jnj-4528, a bcma-directed car-t-cell therapy, in rrmm
-
4:40
cartitude-2 trial update and management of neurotoxicities